Morningstar Q2 2026: Strong Beat Validates Index Pivot as Stock Remains Deeply Undervalued

What happened

Morningstar delivered a strong Q2 2026, beating revenue and EPS estimates with 9.6% top-line growth and 29.2% non-GAAP EPS expansion, signaling that the CRSP acquisition and index-platform strategy are beginning to translate into faster financial momentum. The stock, however, still trades at just 15.6x forward earnings—well below its historical 35–40x range—and at a deep discount to its $246.40 fair value estimate, reflecting lingering market skepticism around Vanguard concentration and monetization. The results provide early evidence that organic index adoption and cross-selling are gaining traction, reducing the probability of the bear case outlined in earlier reports. Morningstar’s 15-year dividend growth streak, conservative payout ratio, and robust free cash flow generation continue to support shareholder returns while it integrates CRSP. The disconnect between improving fundamentals and a subdued valuation creates a compelling setup, though the stock remains a ‘show-me’ story until index revenue acceleration is sustained over multiple quarters.

Implication

The strong quarter lowers downside risk and supports a gradual re-rating if index segment growth proves durable. However, Vanguard concentration remains a key overhang that justifies part of the valuation discount. Investors should focus on whether the 9.6% revenue growth can be sustained and if margins expand as integration costs fade. The fair value estimate of $246.40 versus the current price offers a wide margin of safety, but patience is needed as the market demands more evidence of competitive advantage. Near-term catalysts include further third-party index mandate wins and clarity on the long-term Vanguard agreement.

Thesis delta

The Q2 2026 beat shifts the thesis from a cautious ‘wait-and-see’ to early validation, as faster-than-expected monetization of the CRSP acquisition reduces the risk that index scale fails to convert into earnings. While Vanguard concentration risk persists, the deeper valuation discount and strong growth improve the risk/reward, warranting higher conviction in the undervaluation case.